Get the Latest Funding and Biotech News

Gibela publishes groundbreaking research in Hepatology

We are pleased to share that the research of Gibela Therapeutics, our portfolio company, was featured on the cover of the Hepatology journal. The company is…

Synendos Appoints Dr. George Garibaldi as Chief Medical Officer

Basel, Switzerland – Synendos Therapeutics, the clinical-stage biotechnology company developing breakthrough therapies for neuropsychiatric disorders, announced the appointment of Dr. George Garibaldi as Chief Medical…

We welcome BioDuro as our new domain partner

We’re excited to share our new partnership with BioDuro, a trusted CRDMO with a 29-year proven track record and strong reputation for delivering high-quality, end-to-end…

BaseLaunch Summer Get-Together 2025

Our summer get-together brought people from across the biotech ecosystem, from founders and scientists, to investors, partners, and beyond, for an evening that combined meaningful…

Navigating US & EU Patent Law for Startups – avoiding the common pitfalls

Navigating US & EU Patent Law for Startups – avoiding the common pitfalls If you want to protect your intellectual property with a patent, you…

Phialogics AG announces the appointment of Dr. Debra Barker as Chief Medical Officer

Allschwil, Switzerland – 10 June, 2025 – Phialogics AG announces the appointment of Dr. Debra Barker as Chief Medical Officer. Dr. Barker joins Phialogics with…

Hemastatx joins BaseLaunch portfolio

We’re excited to welcome Hemastatx to our portfolio. Hemastatx, a spin-off from KU Leuven, has emerged from stealth with funding from BaseLaunch, Gemma Frisius Fund and…

metaLead secures CHF 1 million investment to advance novel therapy for Wilson disease

Basel, Switzerland – May 5, 2025 – metaLead Therapeutics AG (metaLead), a pioneering biotech company developing next-generation metal-binding therapies, announced today that it has secured…

Filing intellectual property (IP) on novel targets and epitopes

Filing intellectual property (IP) on novel targets and epitopes Building a strong IP portfolio is complex, especially when securing patents for novel targets and epitopes.…

Ilonov joins BaseLaunch portfolio

Ilonov is harnessing groundbreaking discoveries to revolutionize treatment for metabolic disorders. By harvesting novel targets discovered from breakthrough research on the human muscle secretome, the…

Phialogics appoints Dr. Natalia Novac as Chief Executive Officer

Basel, Switzerland – 10 Feb, 2025, Phialogics AG has announced the appointment of Dr. Natalia Novac as Chief Executive Officer. Natalia has a great experience…

Gibela Therapeutics joins BaseLaunch portfolio

Gibela Therapeutics, a spin-off from the Cooperative Research Center in Biosciences (CIC bioGUNE), is pioneering RNA-based therapeutics for the treatment of liver diseases. The company,…

What’s the ideal deal structure to secure funding for biotech startups?

What’s the ideal deal structure to secure funding for biotech startups? As the biotech funding environment evolves, particularly in early seed and Series A rounds,…

Alentis announces positive topline results from two studies of Lixudebart

Basel, Switzerland – 9 Jan, 2025, Alentis Therapeutics, a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced positive topline…

Anaveon appoints Dr. Richard Sachse as Chief Medical Officer

Basel, Switzerland – 18 Dec, 2024, Anaveon, a clinical stage, immuno-oncology company, today announced the appointment of Richard Sachse, M.D., Ph.D., as Chief Medical Officer…

Stromal publishes groundbreaking research in Cell

We are pleased to share that Stromal Therapeutics have published groundbreaking research in Cell, shedding light on a critical interplay between fibroblasts and the local…

Looking for an experienced biopharma professional for CEO role

One of our preclinical companies is currently looking for an experienced biopharma entrepreneurial-minded CEO. The company specializes in engineering next-generation biologics to rebalance the immune…

Cimeio Therapeutics signs $300M partnership with Kyowa Kirin

Basel, Switzerland and Cambridge, MA – 9 Dec, 2024, Cimeio Therapeutics announced that it has entered a research collaboration with Kyowa Kirin Co., Ltd. (Kyowa…

metaLead joins BaseLaunch portfolio

MetaLead Therapeutics AG, a spin-out from the University of Zurich, is pioneering the field of metal-related diseases by focusing on novel therapeutic approaches for conditions…

Alentis Therapeutics raises $181.4 million in an oversubscribed series D financing

Basel, Switzerland – 12 Nov, 2024, The BaseLaunch portfolio company Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and…

Synendos secures Innosuisse funding to advance clinical development of SYT-510

Synendos AG, a BaseLaunch portfolio company, has been awarded a prestigious grant under the Start-Up Innovation Project (SIP) scheme by Innosuisse. This highly competitive initiative…

Key strategies for biotech companies transitioning from early- to late-stage

Transitioning from early- to late-stage development is a pivotal phase for any biotech startup. This journey, often laden with both opportunities and challenges, requires a…

Alentis Therapeutics receives FDA IND clearance for ALE.P02, a novel CLDN1-ADC for the treatment of squamous cancers

Basel, Switzerland – 2 Oct, 2024, Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced yesterday…

MT-act joins BaseLaunch portfolio

MT-act spun out from the Institute of Human Genetics and CNRS in Montpellier, leverages recent advances in understanding cytoskeleton stiffness and its influence on age-related…

We welcome Hoffmann & Partner as our new domain partner

We’re pleased to announce a partnership with Hoffmann & Partner AG, a well-regarded firm specializing in mergers & acquisitions (M&A) and CFO services. With over…

BaseLaunch summer get-together 2024

We were pleased to have so many experts, partners, and friends joining the BaseLaunch Summer get-together on Wednesday last week. It was a great opportunity…

NXI Therapeutics extends pre-seed funding to CHF 3.5 million ahead of major seed round

NXI Therapeutics AG, developer of tomorrow’s disruptive immunotherapies by coronin 1 modulation, today announces the extension of a pre-seed financing totalling to 3.5 million CHF.…

9 tips for scientists who want to become entrepreneurs

9 tips for scientists who want to become entrepreneurs In our latest event, hosted in Strasbourg and co-organized with KPMG, we explored what it takes…

Nature publication demonstrating Cimeio`s transformative approach towards blood cancers

Cimeio Therapeutics today announced a publication in Nature showing that its CD45 antibody-drug conjugate (ADC) eradicated aggressive leukemic cells in vivo, while hematopoiesis was fully preserved and…

AbbVie becomes a BaseLaunch partner

AbbVie joins other pharmaceutical, venture fund and biotechnology partners supporting BaseLaunch’s company creation endeavours. BaseLaunch’s mission is to help scientists and entrepreneurs build exceptional biotech…

Alentis appoints Alberto Toso Chief Scientific Officer

Basel, Switzerland – 29 April, 2024, Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today…

Our partnership with CSL

BaseLaunch is excited to announce the extension of the partnership with CSL, a global biotech leader. Together, we're committed to driving innovation in healthcare. CSL’s…

We welcome VISCHER as our new domain partner

We are pleased to announce a partnership with VISCHER, a respected Swiss law firm known for its commitment to providing startups, entrepreneurs and investors with…

Podcast: How to build a compelling pitch deck for early stage ventures

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch the attention of investors.For biotech…

KPMG renews partnership with BaseLaunch

We are delighted to announce that KPMG, is continuing its partnership with BaseLaunch to help support cutting-edge early-stage biotechs to achieve financing and grow their…

FimmCyte obtains CHF 1 million from the UZH Life Sciences Fund

FimmCyte, a pioneering women's health biotech, announces an investment of 1 million CHF as a convertible loan from the UZH Life Sciences Fund (LSF). FimmCyte’s…

Synendos Therapeutics granted EMA clinical trial authorisation

BASEL, Switzerland, 18 January 2024 - Synendos Therapeutics AG, a world leader in innovative Endocannabinoid System (ECS) treatments, today announces that it has received approval…

William Pao joins Alentis Therapeutics as independent board member

Basel, Switzerland – Alentis Therapeutics , a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today that Dr. William…

Novo Nordisk becomes a BaseLaunch partner

Novo Nordisk has become the latest partner to join BaseLaunch. Novo Nordisk joins other world-class pharma, venture fund and biotechnology partners - Roche, Johnson &…

Engimmune Therapeutics strikes ‘fast-forward’ micro-fluidics collaboration with Swiss innovator CSEM

Basel, Switzerland, 13 December, 2023 – Engimmune Therapeutics AG (“Engimmune”), a world-class developer of soluble T-cell receptor drugs (‘TCRs’) to treat solid tumours, is pleased…

Ferring and PharmaBiome enter a collaboration and exclusive licensing agreement

Ferring Pharmaceuticals and PharmaBiome announced a research & development collaboration to drive forward new microbiome-based biotherapeutics in the field of gastroenterology. The deal provides Ferring…

TOLREMO treats first patient in phase I trial with TT125-802, a novel therapeutic agent to overcome transcriptional cancer drug resistance

TOLREMO today announced that the first patient has been dosed in its first-in-human clinical trial evaluating the safety and tolerability, pharmacokinetics, and pharmacodynamics of its…

T3 Pharma acquired by Boehringer Ingelheim for up to 450M Swiss francs

Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma. Boehringer Ingelheim today announced the acquisition of privately-held T3 Pharma…

FDA clears Versameb’s VMB-100 for stress urinary incontinence treatment

Versameb AG, a leading pre-clinical stage biotechnology company, has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND)…

Alentis Therapeutics doses first patient in phase 1/2 clinical trial of ALE.C04

This first-in-human study evaluates the safety, tolerability and efficacy of ALE.C04 as a monotherapy and in combination.Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company within our portfolio…

FimmCyte announces the appointment of Dr. Markus Kalousek as chairperson

Dr. Markus Kalousek takes on the role of Chairperson at FimmCyte, a pioneering women's health biotech, starting from 1 Nov 2023. With over 25 years in…

Onena Medicines secures 3.7 M Swiss francs investment

Onena Medicines closes 3.7M CHF funding round to advance its novel DSIP targeting antibody portfolio.Onena Medicines AG, a cellular reprogramming platform drug discovery company, announced…

Johnson & Johnson Innovation renews its commitment

We are delighted to announce that Johnson and Johnson is continuing its partnership with BaseLaunch to help support cutting-edge early-stage biotechs to achieve financing and…

Cimeio collaborating with the University of Pennsylvania

Cimeio Therapeutic, headquartered in Basel with a subsidiary located in Cambridge, Massachusetts, is to carry out further research and evaluate its novel, universal immunotherapy for…

Insights into Roche’s partnering and venture fund strategies

Insights into Roche's partnering and venture fund strategies In our biotech networking event with Roche, powered by Innosuisse, we explored the path from pioneering scientific…

Salvina Therapeutics joins BaseLaunch portfolio

Salvina Therapeutics AG, a recently founded Swiss company, is developing new therapies to break efficacy ceilings in inflammatory and autoimmune diseases. The company has unlocked…

TOLREMO therapeutics secures USD 39 million

Basel, 20 September, 2023 – The Swiss biotech company TOLREMO therapeutics AG recently completed a successful Series A financing, bringing the total amount raised to…

Alentis Therapeutics receives FDA Fast Track Designation for ALE.C04

We are pleased to announce that Alentis Therapeutics, a company within our portfolio, has been granted fast track designation by the US FDA for its…

What you need to know about building your biotech startup

What you need to know about building your biotech startup What do biotech entrepreneurs need to navigate the biotech landscape successfully? In the ”Beyond biotech”…

BaseLaunch Summer Get-Together 2023

We are very pleased to have had so many experts, partners, and friends joining our Summer Get-together this year! It was an incredible day filled…

Versameb strengthens its Board of Directors

Versameb, transforming (m)RNA therapeutics to cure hard-to-treat and/or prevalent diseases, is pleased to announce the appointments of Hernán Levett, Dr Lily Geidelberg, Paul Korner, MD,…

Cimeio Therapeutics and Prime Medicine announce research collaboration

Our portfolio company, Cimeio Therapeutics, a biotechnology company that is reinventing cell therapy through its leadership in the emerging field of epitope shielding, and Prime…

How Swiss life sciences startups can compete globally

How Swiss life sciences startups can compete globally In this biotech networking event, Johnson & Johnson Innovation shared their approach towards external innovation and their…

Phialogics AG appoints Prof. Dr. Erich Schlick as Chairman of its Board of Directors

Phialogics AG has announced the appointment of Prof. Dr. Erich Schlick as Chairman of its Board of Directors. Erich was introduced to Phialogics by BaseLaunch…

Phialogics closed a €600k pre-seed financing round with HTGF

Our portfolio company, Phialogics - a preclinical stage company developing cell-type-specific immune checkpoint activators to prevent multi-organ failure in autoimmune diseases, closed a €600k pre-seed…

Engimmune Therapeutics appoints Dr. Lars Nieba as Chief Executive Officer

Engimmune Therapeutics, a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, has announced the appointment of Dr. Lars Nieba as Chief Executive Officer. Engimmune…

BaseLaunch Portfolio has raised over half a billion dollars to date!

We are delighted to announce that our portfolio has blown past half a billion dollars raised to now collectively reach over $550M! Just the last…

Alentis Therapeutics closes $105M funding round Led by Jeito Capital, Novo Holdings and RA Capital Management

Alentis Therapeutics is a thriving clinical-stage biotech company in Basel, Switzerland, developing breakthrough treatments for organ fibrosis and CLDN1 positive tumors. The company, lead by…

FimmCyte joins BaseLaunch Portfolio

Endometriosis is a painful and debilitating condition that affects one in every ten women. Despite being a common health issue, there are currently limited treatment…

What startups need to know about term sheets, legal due diligence and employee incentives

What startups need to know about term sheets, legal due diligence and employee incentives Conducting legal due diligence and preparing and negotiating term sheets for…

Building biotech companies and raising venture capital financing

Building biotech companies and raising venture capital financing In our latest event co-organized with Pureos, we had three extraordinary biotech founders (one of them who…

Raising $50M series A with Cimeio Therapeutics

NXI Therapeutics Expands Management Team and Board Ahead of Next Growth Stage

NXI Therapeutics (formerly Nextimmune), the specialist biotech developing next generation immunosuppressive drugs for autoimmune diseases and organ transplantation, today announces that it has appointed Dr…

News